SCHEMBL1407007

SCHEMBL1407007

CCN(CC)c1ccc(-c2cc(C(O)/C=C/c3ccc(C(=O)O)cc3)cc3c2C(C)(C)CCC3(C)C)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 10/20 0.62
RARG P13631 10/20 0.62
RARA P10276 8/20 0.62
RXRA P19793 9/20 0.45
RXRB P28702 5/20 0.45
RXRG P48443 4/20 0.45
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.41
THRB P10828 2/20 0.41
PKM P14618 2/20 0.41
HPGD P15428 2/20 0.41
MAPK1 P28482 2/20 0.41
MDM2 Q00987 2/20 0.41
KMT2A Q03164 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
TNNI3 P19429 1/20 0.41
TNNT2 P45379 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1407009 1.00 RARB (0.62) RARBRARGRARARXRARXRB
SCHEMBL1406504 0.91 RARB (0.64) RARBRARGRARARXRARXRB
SCHEMBL1406502 0.91 RARB (0.64) RARBRARGRARARXRARXRB
SCHEMBL1406710 0.88 RARA (0.46) RARBRARGRARARXRARXRB
SCHEMBL1406709 0.88 RARA (0.46) RARBRARGRARARXRARXRB
SCHEMBL1406496 0.88 RARG (0.67) RARBRARGRARARXRARXRB
SCHEMBL1406495 0.88 RARG (0.67) RARBRARGRARARXRARXRB
SCHEMBL1406310 0.86 RARB (0.65) RARBRARGRARARXRARXRB
SCHEMBL1406309 0.86 RARB (0.65) RARBRARGRARARXRARXRB
SCHEMBL1406886 0.85 RARB (0.66) RARBRARGRARARXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP claimed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US claimed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US claimed
EP-1513793-B1 NOVEL LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS GALDERMA RES & DEV (FR) 2011-03-09 EP disclosed
US-7468457-B2 Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT (FR) 2008-12-23 US disclosed
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050131033-A1 Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof RARA, RARB, RARG RARB 2/4885RARG 3/4885RARA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.